Video

Pharmaceutical CEO Leadership: Diversity in Pharma - Internal Culture

In this segment, members of the Pharmaceutical CEO Leadership: Diversity in Pharma panel treat culture as the soul of an organization and value diversity of thought among employees. They also support instilling guiding principles that can help reduce rulemaking and streamline everyday decisions. The idea of using culture as a strategic weapon is also discussed.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Gen Li
Gen Li
Gen Li
Dr. Ben Zeskind
Gen Li
Dr. Ben Zeskind
Gen Li
Dr. Ben Zeskind
Related Content
GAIN Therapeutics Ramps Up for Next Big Step in Parkinson’s Drug Development
August 5th 2025

GAIN Therapeutics Ramps Up for Next Big Step in Parkinson’s Drug Development

Don Tracy, Associate Editor
Gene Mack, CEO, GAIN Therapeutics, outlines how early trial results for GT-02287 are shaping the company’s strategy for advancing a potential new treatment for Parkinson’s disease.
Early Trial Success Signals Promise for GT-02287 in Parkinson’s Disease Treatment
August 5th 2025

Early Trial Success Signals Promise for GT-02287 in Parkinson’s Disease Treatment

Don Tracy, Associate Editor
Gene Mack, CEO, GAIN Therapeutics, shares how growing clinician confidence and strong early experiences helped accelerate enrollment in the company’s Phase Ib Parkinson’s disease trial.
Exploring the Promise of E7386 and Lenvatinib Combination Therapy in Endometrial Carcinoma
August 5th 2025

Exploring the Promise of E7386 and Lenvatinib Combination Therapy in Endometrial Carcinoma

Don Tracy, Associate Editor
Corina Dutcus, SVP, oncology global clinical development lead at Eisai, discusses the potential of the E7386 and lenvatinib combination to address unmet needs in second-line treatment for endometrial carcinoma patients.
Collaborating for Smarter AI Solutions in Oncology at Johnson and Johnson
August 5th 2025

Collaborating for Smarter AI Solutions in Oncology at Johnson and Johnson

Don Tracy, Associate Editor
Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, discusses the importance of collaboration across the healthcare community to develop inclusive and effective AI solutions that enhance decision-making and patient outcomes in oncology.
AbbVie Positions Temab-A ADC for Tumor-Agnostic Use in Multiple Cancers
August 5th 2025

AbbVie Positions Temab-A ADC for Tumor-Agnostic Use in Multiple Cancers

Don Tracy, Associate Editor
Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, explains how the company is advancing Temab-A across multiple tumor types targeting c-Met, with the goal of establishing it as a pipeline-in-a-molecule.
What Drives AbbVie’s Solid Tumor Strategy Following ASCO 2025 Insights
August 5th 2025

What Drives AbbVie’s Solid Tumor Strategy Following ASCO 2025 Insights

Don Tracy, Associate Editor
Pedro Valencia, VP, asset strategy leadership, oncology, outlines how unmet need, treatment stagnation, and pipeline innovation shape the company’s approach to solid tumor oncology following key data presented at ASCO 2025.